Reliance Medical Offering New Tools for Cardiac Risk Assessment

The Woodlands, TX, January 10, 2013 --(PR.com)-- Leading US medical equipment supplier Reliance Medical has announced that the company has introduced new equipment to their expanding catalogue. The latest addition to the organization’s catalogue, the EndoPat™, is considered to be the new leading product for cardiac risk assessment available in the modern marketplace.

For the modern medical professional, achieving a prompt patient diagnosis is imperative. That’s why today’s doctors and nurses must have at their disposal tools such as the EndoPat™. The EndoPat™ is ideal because it allows medical assistants to complete complex endothelial assessment tests within just 15 minutes in an office-style environment. And for the patient, each of these tests is reimbursable by Medicare and commercial insurance, therefore reducing the financial burden of achieving precise, fast diagnosis of potential endothelial function issues.

Results of the test can be seen by professionals immediately upon completion, ensuring that swift medical care can be administered should the cardiac risk assessment tool pick up on any issues that the patient might be experiencing. This means that patients can limit the anxious wait for results and immediately begin recuperating from potential problems, therefore reducing the negative health impact of such issues.

The EndoPat™ is one of the most popular tools now utilized in medical offices across North America. And study after study has shown the product’s efficacy in helping ensure accuracy and fast diagnosis for patients. To learn more about the product, please visit the Reliance Medical website at www.reliancemedicalsystems.com or contact the company directly and speak with one of their highly qualified sales team.